Two-Week test could guide better breast cancer treatment
NCT ID NCT07410559
Summary
This study is testing a new approach for treating a common type of breast cancer before surgery. Patients first get a two-week course of two targeted drugs. Doctors then check a tumor marker (Ki67) to decide if they should continue with the drug combo or switch to standard chemotherapy. The goal is to see if this personalized plan is effective and safe for women with ER-positive, HER2-negative breast cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.